Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

CREATES Act To Face Major Reshaping By Innovator-Friendly Amendments On Senate Floor

The Creating and Restoring Equal Access to Equivalent Samples Act clears US Senate Judiciary Committee.  During markup, Sens. Hatch, R-Utah, and Cornyn, R-Tex., preview future amendments that would benefit innovators.

Legislation Generic Drugs

Shifting Medicare Part B Drugs To Part D: Legislative Prospects Cloudy

Democrats on US Senate Health Committee express concern that patient cost sharing could increase significantly with the change.

Pricing Debate Medicare

Big Pharma Voluntary List Price Reductions Doubtful, Sen. Warren Says

Companies responding to inquiries from Sens. Elizabeth Warren, D-Mass., and Tina Smith, D-Minn., did not indicate they are planning to reduce list prices, despite promises by President Trump, Warren told a June 12 hearing. 
Pricing Debate Pharmacy Benefit Management

Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

HHS Secretary Azar explains why companies have not voluntarily lowered prices as yet, despite President Trump’s recent comments. He also discussed using regulations to prohibit rebates.

Pricing Debate Medicare

Lowering Insulin Costs: Sanofi Seeks HHS Support For Expanding Assistance To Medicare Patients

HHS endorsement of company-sponsored discount programs for cash-paying customers with Medicare would be preferable to lowering list pricing.

Pricing Debate Medicare

Medicare Part D Spending Projected To Decline in 2018 As Rebates Increase

Part D plans project rebates will increase to 25.3% of total drug costs in their bids for the 2018 benefit year, the recently-released Medicare Trustees Report notes.

Pricing Strategies Medicare
See All
Advertisement
UsernamePublicRestriction

Register